Journal Mobile Options
Table of Contents
Vol. 45, No. 3, 1973
Issue release date: 1973
Int Arch Allergy 1973;45:467–478
(DOI:10.1159/000231064)
Paper

Studies with Two New Phosphodiesterase Inhibitors (ICI 58,301 and ICI 63,197) on Anaphylaxis in Guinea Pigs, Mice and Rats

Davies G.E. · Evans D.P.
Imperial Chemical Industries Limited, Pharmaceuticals Division, Alderley Park, Macclesfield, Cheshire

Abstract

Two compounds, ICI 58,301 (3-acetamido-6-methyl-8-n-propyl-s-triazolo[4,3-a]pyrazine) and ICI 63,197 (2-amino-6-methyl-5-oxo-4-n-propyl-4,5,-dihydro-s-triazolo[l,5-a]pyrimidine) facilitate the recovery of guinea pigs which have been subjected to anaphylactic shock. ICI 63,197 also reduces the amount of histamine released from the isolated lungs of sensitized guinea pigs after injection of antigen, partially inhibits passive cutaneous anaphylaxis in guinea pigs, protects mice from anaphylactic shock, and inhibits passive cutaneous anaphylaxis in rats sensitized with homologous reaginic or heterologous antisera. ICI 58,301 is not active in these conditions. Both compounds are potent inhibitors of 3′:5′-cyclic AMP phosphodiesterase and it is speculated that this property is associated with their anti-anaphylactic effects.

 goto top of outline Author Contacts

Request reprints from: Dr. G. E. Davies, Imperial Chemical Industries Ltd., Pharmaceuticals Division, Alderley Park, Macclesfield, Cheshire (UK)


 goto top of outline Article Information

Received: April 11, 1973
Published online: July 23, 2009
Number of Print Pages : 12


 goto top of outline Publication Details

International Archives of Allergy and Immunology

Vol. 45, No. 3, Year 1973 (Cover Date: 1973)

Journal Editor: Valenta R. (Vienna)
ISSN: 1018-2438 (Print), eISSN: 1423-0097 (Online)

For additional information: http://www.karger.com/IAA


Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.